ClinicalTrials.gg
CompletedNCT04120402SPRINGBOARDUpdated Jun 25, 2024Results posted

Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

A Phase 2 interventional study of EP-104IAR 25 mg and Vehicle in Osteoarthritis, Knee, sponsored by Eupraxia Pharmaceuticals Inc.. Completed at 12 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by Eupraxia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.

Enrollment
23rd of 72
318 · median 115
Started
2021
with 5 others
Phase 2
13 of 78
none open now
Registered
26th of 78
by date

Among the 78 studies in Osteoarthritis, Knee with a site in Poland, this one is the 23rd largest by enrollment of the 72 interventional ones that give a count, is one of 6 that started in 2021, is one of 13 in phase 2, and was the 26th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 78 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Osteoarthritis, Knee with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of EP-104IAR in patients with osteoarthritis (OA) of the knee

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single injection, 24-week study to evaluate the safety, efficacy and PK of EP-104IAR in subjects with osteoarthritis knee pain

Following screening and baseline assessments to determine eligibility, each participant will receive a single IA injection of either EP-104IAR or placebo (vehicle). Participants will be followed up for 24 weeks following the injection for safety, PK and efficacy assessments.

03

Conditions studied

  • Osteoarthritis, Knee
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males or females, aged ≥40 years
  • (BMI) ≤ 40.0 kg/m2
  • Diagnosis of primary OA of the Index knee, with symptoms present for at least 6 months
  • OA severity Grade 2 or 3 (based on Kellgren Lawrence Grading Scale)
  • Unsatisfactory pain relief from at least 2 prior standard OA treatments
  • Qualifying pain in the Index knee during the baseline period
  • Ambulatory (without the need for a cane/other walking aide)
  • Female subjects willing to use highly effective methods to prevent pregnancy
  • Willing and able to comply with study procedures and restrictions, including abstaining from use of restricted medications.

Key Exclusion Criteria:

  • OA of the Index knee due to acute injury or trauma, or unstable joint
  • X-ray evidence of chondrocalcinosis
  • Diagnosed or suspected ipsilateral hip OA
  • Knee pain that is not attributable to OA of the knee
  • Any other disorders that impact mobility, strength or sensation, or are a co-existent source of pain or inflammation that interfere with assessment of knee pain and function
  • History of infection in the Index knee
  • Skin breakdown on the Index knee where the injection will take place
  • Total Knee Replacement, or any other surgery (including arthroscopy) for the Index knee within prior 12 months, or planned surgery during the study
  • Total Knee Replacement Surgery of the non-Index knee within prior 6 months, or planned surgery (any location) during the study that would require a restricted medication
  • IA injection of in any joint within prior 3 months or IA injection of extended-release corticosteroids in any joint within prior 6 months
  • IA injection in the Index knee of rich plasma, or other prolotherapy within prior 3 months, or hyaluronic acid within prior 6 months
  • Recent, current or planned use of corticosteroids for any indication (except for permitted uses)
  • Recent, current or planned use of prohibited medications (including analgesics, marijuana, drugs and devices, therapy), or unwilling or unable to stop using prohibited medications during the study.
  • Conditions including: sarcoidosis, amyloidosis, osteomyelitis, Cushing's Syndrome, hepatic or renal disease, Psychotic disorder, bipolar disorder, symptomatic depressive or anxiety disorders.
  • Current of any type, or history of a malignancy within prior 12 months
  • Active or quiescent systemic fungal, bacterial (including tuberculosis) viral (including , or C) or parasitic infections, or ocular herpes simplex, or any recent infection requiring IV or oral antibiotics
  • Laboratory results indicative of adrenal insufficiency, diabetes or renal or hepatic disease.
  • Positive urine drug screen for a substance of abuse
  • Females who are pregnant, lactating
  • Known or suspected or to ingredients in the study drug
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    EP-104IAR 25 mg

    A single use intra-articular injection containing 25 mg of EP-104IAR

    Drug: EP-104IAR 25 mg

  • Placebo comparator
    Placebo (vehicle)

    A single use intra-articular injection containing no active ingredients

    Drug: Vehicle

Interventions

  • DrugEP-104IAR 25 mg

    Single 5 mL intra-articular injection

  • DrugVehicle

    Single 5 mL intra-articular injection

06

What researchers measure

Primary outcomes

  1. Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (scores scaled 0-10, with 10 being the worst). Least squares mean from a mixed model for repeated measures (MMRM) for change from baseline with fixed effects for site, treatment, week, treatment-by-week interaction; random effect for subject; and covariate baseline WOMAC pain score.

    Time frame: 12 weeks

Secondary outcomes

  1. Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Function Subscale

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale (scores scaled 0-10, with 10 being the worst). Function subscale includes questions related to the physical functioning of osteoarthritis e.g. stair use, standing, walking etc. From a mixed model for repeated measures (MMRM) for change from baseline with fixed effects for site, treatment, week, treatment-by-week interaction; random effect for subject; and covariate baseline WOMAC function score.

    Time frame: 12 weeks

  2. Difference Between EP-104IAR and Vehicle in the Area Under the Curve (AUC) of WOMAC Pain Subscale

    Area under the curve in change from baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (scores scaled 0-10, with 10 being the worst) from Week 0 to Week 12 was calculated on a per-individual basis using the linear trapezoidal rule. AUC was normalized to account for subjects whose actual days and nominal days at Week 12 differed. Treatments were compared using an ANCOVA model containing site; individual baseline WOMAC Pain; and treatment group as covariates.

    Time frame: 12 weeks

  3. Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (scores scaled 0-10, with 10 being the worst). Least squares mean from a mixed model for repeated measures (MMRM) for change from baseline with fixed effects for site, treatment, week, treatment-by-week interaction; random effect for subject; and covariate baseline WOMAC pain score.

    Time frame: 24 weeks

  4. Difference Between EP-104IAR and Vehicle in OMERACT-OARSI Strict Responders

    Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) strict responders are defined as at least 50% improvement (decrease from baseline) in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain or function subscales (scores scaled 0-10, with 10 being the worst) and an absolute change of at least 2 in the respective score. Patients who discontinued prior to Week 12 were considered non-responders.

    Time frame: 12 weeks

07

Results

Posted Jun 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneEP-104IAR 25 mgPlacebo (Vehicle)
Started163155
Completed156148
Not completed77

Outcome measures

PrimaryDifference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (scores scaled 0-10, with 10 being the worst). Least squares mean from a mixed model for repeated measures (MMRM) for change from baseline with fixed effects for site, treatment, week, treatment-by-week interaction; random effect for subject; and covariate baseline WOMAC pain score.

Time frame:
12 weeks
Reported as:
Least squares mean · score on a scale
Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale
score on a scaleEP-104IAR 25 mgPlacebo (Vehicle)
Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale-2.89 ± 0.166-2.23 ± 0.171
Statistical analysis
  • EP-104IAR 25 mg vs Placebo (Vehicle) · ANCOVA · p = 0.004
SecondaryDifference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Function Subscale

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale (scores scaled 0-10, with 10 being the worst). Function subscale includes questions related to the physical functioning of osteoarthritis e.g. stair use, standing, walking etc. From a mixed model for repeated measures (MMRM) for change from baseline with fixed effects for site, treatment, week, treatment-by-week interaction; random effect for subject; and covariate baseline WOMAC function score.

Time frame:
12 weeks
Reported as:
Least squares mean · score on a scale
Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Function Subscale
score on a scaleEP-104IAR 25 mgPlacebo (Vehicle)
Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Function Subscale-2.59 ± 0.161-2.04 ± 0.166
Statistical analysis
  • EP-104IAR 25 mg vs Placebo (Vehicle) · ANCOVA · p = 0.014
SecondaryDifference Between EP-104IAR and Vehicle in the Area Under the Curve (AUC) of WOMAC Pain Subscale

Area under the curve in change from baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (scores scaled 0-10, with 10 being the worst) from Week 0 to Week 12 was calculated on a per-individual basis using the linear trapezoidal rule. AUC was normalized to account for subjects whose actual days and nominal days at Week 12 differed. Treatments were compared using an ANCOVA model containing site; individual baseline WOMAC Pain; and treatment group as covariates.

Time frame:
12 weeks
Reported as:
Least squares mean · score on a scale multiplied by days
Difference Between EP-104IAR and Vehicle in the Area Under the Curve (AUC) of WOMAC Pain Subscale
score on a scale multiplied by daysEP-104IAR 25 mgPlacebo (Vehicle)
Difference Between EP-104IAR and Vehicle in the Area Under the Curve (AUC) of WOMAC Pain Subscale-235.67 ± 11.769-166.78 ± 12.169
Statistical analysis
  • EP-104IAR 25 mg vs Placebo (Vehicle) · ANCOVA · p = <0.001
SecondaryDifference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (scores scaled 0-10, with 10 being the worst). Least squares mean from a mixed model for repeated measures (MMRM) for change from baseline with fixed effects for site, treatment, week, treatment-by-week interaction; random effect for subject; and covariate baseline WOMAC pain score.

Time frame:
24 weeks
Reported as:
Least squares mean · score on a scale
Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale
score on a scaleEP-104IAR 25 mgPlacebo (Vehicle)
Difference in Change From Baseline Between EP-104IAR and Vehicle in WOMAC Pain Subscale-2.26 ± 0.171-2.11 ± 0.175
Statistical analysis
  • EP-104IAR 25 mg vs Placebo (Vehicle) · ANCOVA · p = 0.518
SecondaryDifference Between EP-104IAR and Vehicle in OMERACT-OARSI Strict Responders

Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) strict responders are defined as at least 50% improvement (decrease from baseline) in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain or function subscales (scores scaled 0-10, with 10 being the worst) and an absolute change of at least 2 in the respective score. Patients who discontinued prior to Week 12 were considered non-responders.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Difference Between EP-104IAR and Vehicle in OMERACT-OARSI Strict Responders
ParticipantsEP-104IAR 25 mgPlacebo (Vehicle)
Difference Between EP-104IAR and Vehicle in OMERACT-OARSI Strict Responders8761
Statistical analysis
  • EP-104IAR 25 mg vs Placebo (Vehicle) · Fisher Exact · p = 0.028

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were summarized and analyzed for safety evaluations i.e, events which occurred from the time of the EP-104IAR or vehicle injection procedure until the Week 24/End-of-Study/Early Exit Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EP-104IAR 25 mg0/163 (0%)4/163 (2.5%)76/163 (46.6%)
Placebo (Vehicle)0/155 (0%)1/155 (0.6%)68/155 (43.9%)
Most frequent serious events
Most frequent serious events
EventEP-104IAR 25 mgPlacebo (Vehicle)
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1631/155
Cerebrovascular accidentNervous system disorders1/1630/155
Accidental overdoseInjury, poisoning and procedural complications1/1630/155
Loss of consciousnessNervous system disorders1/1630/155
Acute vestibular syndromeEar and labyrinth disorders1/1630/155
Most frequent other events
Most frequent other events
EventEP-104IAR 25 mgPlacebo (Vehicle)
ArthralgiaMusculoskeletal and connective tissue disorders38/16323/155
COVID-19Infections and infestations14/16314/155
NasopharyngitisInfections and infestations14/16312/155
Influenza like illnessGeneral disorders4/16310/155
InfluenzaInfections and infestations6/1639/155

Baseline characteristics

The intention-to-treat (ITT) population consisted of all subjects who were both randomized to and received treatment. Analysis was conducted allocating subjects to the treatment to which they were randomized, irrespective of what was actually received. The safety population consisted of all randomized subjects who were administered a dose of study drug. The subjects in this group were analyzed based on the treatment they received.

Age, Categorical
Age, Categorical(Participants)EP-104IAR 25 mgPlacebo (Vehicle)Total
<=18 years000
Between 18 and 65 years9189180
>=65 years7266138
Age, Continuous
Age, Continuous(years)EP-104IAR 25 mgPlacebo (Vehicle)Total
Mean64.0 ± 9.3163.2 ± 9.3763.6 ± 9.33
Sex: Female, Male
Sex: Female, Male(Participants)EP-104IAR 25 mgPlacebo (Vehicle)Total
Female9489183
Male6966135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EP-104IAR 25 mgPlacebo (Vehicle)Total
Hispanic or Latino123
Not Hispanic or Latino161152313
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EP-104IAR 25 mgPlacebo (Vehicle)Total
American Indian or Alaska Native011
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White162153315
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)EP-104IAR 25 mgPlacebo (Vehicle)Total
Czechia403575
Denmark8584169
Poland383674
08

Study locations

12 sites
  • CCR Brno, s.r.o
    Brno, Czechia
  • CCR Czech a.s
    Pardubice, Czechia
  • CCR Prague, s.r.o
    Prague, Czechia
  • The Parker Institute, Frederiksberg Hospital
    Frederiksberg, Denmark
  • Sanos Clinic Nordjylland
    Gandrup, Denmark
  • Sanos Clinic Herlev
    Herlev, Denmark
  • Sanos Clinic Syddanmark
    Vejle, Denmark
  • NZOZ BIF-MED s.c
    Bytom, Poland
  • Medyczne Centrum Hetmańska
    Poznań, Poland
  • Somed CR
    Warsaw, Poland
  • Somed CR
    Łódź, Poland
  • DC-MED
    Świdnica, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2023, 20 months.

Results were first posted in Jun 2024, 1 year 1 month after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2019
First posted
Oct 9, 2019
StartActual
Sep 10, 2021
Primary completionActual
May 17, 2023
CompletionActual
Jun 1, 2023
Results first posted
Jun 25, 2024
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04120402
Lead sponsor
Eupraxia Pharmaceuticals Inc.
Collaborators
NBCD A/S
Responsible party
Sponsor
First posted
Oct 9, 2019
Start date
Sep 10, 2021
Primary completion
May 17, 2023
Completion
Jun 1, 2023
Results posted
Jun 25, 2024
Last update
Jun 25, 2024

Study contacts

Amanda Malone
study director · Eupraxia Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion